Sofia Mason, a medical oncologist and doctoral candidate, discusses the results of a trial that validated a multigene RNA signature for guiding chemotherapy choices in early triple negative breast cancer. The trial showed that patients at high risk who received an intensive chemotherapy regimen had a significantly better disease-free survival rate compared to those receiving standard care. The study highlights the potential of using genomic signatures to personalize treatment decisions for patients with triple negative breast cancer. Although the findings may not change management for all oncologists, incorporating predictive tests like this into care pathways could lead to more personalized and targeted treatments in the future.
Source link
Risk prediction in early triple negative breast cancer
